Shares of Pfizer Inc. (NYSE:PFE) ended Friday session in green amid volatile trading. The shares closed up +0.09 points or 0.26% at $34.77 with 14.44 million shares getting traded. Post opening the session at $34.78, the shares hit an intraday low of $34.61 and an intraday high of $34.84 and the price vacillated in this range throughout the day. The company has a market cap of $210.18 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 12:15 p.m. Eastern Daylight Time.
To listen to the webcast, visit our web site at www.pfizer.com and click on the “2016 Wells Fargo Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning now.
Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com.
Shares of Endo International plc – Ordinary Shares (NASDAQ:ENDP) ended Friday session in red amid volatile trading. The shares closed down -0.41 points or -2.03% at $19.82 with 9.61 million shares getting traded. Post opening the session at $20.23, the shares hit an intraday low of $19.21 and an intraday high of $20.58 and the price vacillated in this range throughout the day. The company has a market cap of $
4.51billion and the numbers of outstanding shares have been calculated to be 222.77 million shares.
Endo International plc – Ordinary Shares (ENDP) on Aug. 18, 2016 announced that Rajiv De Silva, President and CEO, has entered into a Rule 10b5-1 stock trading plan in connection with his year-end tax planning. Under the terms of Mr. De Silva’s stock trading plan, an authorized third-party broker will sell up to 13,500 Endo shares beneficially owned by Mr. De Silva, which represents approximately 4 percent of Mr. De Silva’s total Endo stock ownership. The stock trading plan will be completed in September 2016. If all of the planned Endo share sales under Mr. De Silva’s stock trading plan are completed, Mr. De Silva will continue to beneficially own Endo shares with an aggregate market value well in excess of five times his base salary, as required by the Company’s stock ownership guidelines.
The stock trading plan executed by Mr. De Silva was adopted in accordance with Endo’s insider trading policy and the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, which provides an affirmative defense from potential liability for company insiders by permitting them to buy or sell a predetermined amount of their company’s shares as set forth in a planned acquisition or divestiture program which is adopted when the insider does not possess material non-public information. Transactions under Mr. De Silva’s stock trading plan and any other insiders’ stock trading plans will be publicly reported to the U.S. Securities and Exchange Commission in accordance with applicable securities laws, rules and regulations.